6-K - BCTX - Equibles

UNITEDSTATES

SECURITIESAND EXCHANGE COMMISSION

Washington,D.C. 20549

FORM6-K

REPORTOF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of February 2022

Commission File Number: 001-40101

BRIACELLTHERAPEUTICS CORP.

(Translation of registrant’s name into English)

Suite300 – 235 15^th^ Street

WestVancouver, BC V7T 2X1

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☐ Form 40-F ☒

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Exhibit Number	Description
99.1	Press Release dated February 10, 2022 issued by BriaCell Therapeutics Corp.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	BriaCell Therapeutics Corp.
Date:<br> February 10, 2022	By:	/s/ William V. Williams
	Name:	William<br> V. Williams
	Title:	Chief<br> Executive Officer

Exhibit99.1

BriaCellto Present at the AACR 2022; Provides Corporate Buyback and Insider Buying Update

●	BriaCell selected to present at the American Association for Cancer Research (AACR) Annual Meeting 2022
●	Corporate buyback program continues; 1,031,672 shares and 200,740 warrants repurchased since program commencement
●	Insiders intend to acquire up to approximately 10% of BriaCell’s common shares, or 1.59 million shares

PHILADELPHIA and VANCOUVER, British Columbia, February 10, 2022— BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell”or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, has been selected to present at the American Association for Cancer Research (AACR) Annual Meeting 2022 held from April 8 - 13, 2022 at Ernest N. Morial Convention Center, New Orleans, Louisiana. Details include:

**Title:**Toward a personalized off-the-shelf cellular immunotherapy for cancer

SessionCategory: Immunology

SessionTitle: Vaccines: Oncolytic and Prophylactic

SessionDate and Time: Tuesday, April 12, 2022 and 1:30 - 5:00 p.m. CT (2:30 - 6:00 p.m. ET)

**Location:**New Orleans Convention Center, Exhibit Halls D-H, Poster Section 40

PosterBoard Number: 7

PermanentAbstract Number: 3557

Following the presentation, a copy of the poster will be posted on https://briacell.com/scientific-publications/.

CorporateBuyback

Pursuant to the normal course issuer bid securities buyback program (the “Buyback”) announced September 9, 2021, BriaCell has repurchased 1,031,672 common shares (the “Common Shares”) and 200,740 publicly traded BCTXW warrants (the “Listed Warrants”) which have now been cancelled from the total number of shares and warrants outstanding. Common Shares outstanding in the public float now total 14,037,213 and the Listed Warrants outstanding in the public float now total 3,865,817. As announced, BriaCell may purchase through the facilities of the Toronto Stock Exchange, the Nasdaq Capital Market (“Nasdaq”) or alternative exchanges (i) up to 1,341,515 Common Shares and (ii) up to 411,962 publicly traded BCTXW Listed Warrants in total, representing 10% of the outstanding securities comprising the public float as of September 8, 2021.

As of December 13, 2021, the Company had approximately US$52 million in cash with no debt outstanding.

InsiderBuying

As disclosed December 16, 2021, certain members of BriaCell’s Board of Directors and Management team (the “Insiders”) had informed the Company of their intention, on an individual basis and not in concert, to use their personal funds to purchase approximately 10% (1.59 million Common Shares and/or Listed Warrants) of the Company’s Common Shares and Listed Warrants outstanding within the six month period commencing January 31, 2022. Any Insider purchase will be conducted in compliance with the Company’s insider trading policy and Insiders will meet the SEC and TSX reporting obligations. The timing and dollar amount of Insiders’ purchases may vary individually. Purchases of securities by Insiders may coincide with BriaCell’s ongoing Buyback. BriaCell has internal governance procedures in place to execute the Company’s Buyback repurchases independently from any Insiders’ purchase of Securities.

AboutBriaCell Therapeutics Corp.

BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer. More information is available at https://briacell.com/.

SafeHarbor

This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on BriaCell’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading “Risks and Uncertainties” in the Company’s most recent Management’s Discussion and Analysis, under “Risks and Uncertainties” in the Company’s other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under our profiles on SEDAR at www.sedar.com and on EDGAR at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.

Neither Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.

ContactInformation

CompanyContact:

William V. Williams, MD

President & CEO

1-888-485-6340

info@briacell.com

MediaRelations:

Jules Abraham

Director of Public Relations

CORE IR

917-885-7378

julesa@coreir.com

InvestorRelations Contact:

CORE IR

investors@briacell.com